Press Releases

vTv Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

HIGH POINT, N.C.–(BUSINESS WIRE)–Nov. 19, 2018– vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that company management will present a corporate overview at the Piper Jaffray 30th Annual Healthcare Conference on Tuesday, Nov. 27, 2018 at 2:10 p.m. ET in New York City.

A live webcast of the presentation can be accessed here and will be archived for 30

November 19th, 2018|Press Center|

VALASSIS DIGITAL PARTNERS WITH ALLANT GROUP TO DELIVER PRECISION TARGETING SOLUTION FOR MARKETERS

LIVONIA, Mich., Nov. 6, 2018: Valassis Digital, a leading digital marketing intelligence company, announced today its alignment with Allant Group, a nationally recognized data-driven analytics and marketing firm. This partnership provides marketers with an advanced solution connecting robust customer understanding with precise marketing activation.

The combined

November 6th, 2018|Press Center|

SIGA Announces Priority Review Voucher Transaction Totaling $80 Million

NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into an agreement to sell its medical countermeasures priority review voucher (PRV) for a lump sum payment of $80 million. SIGA was

November 1st, 2018|Press Center|

AM General Makes Strategic Investment in Next Generation Artillery System Provider Mandus Group

SOUTH BEND, Ind., and ROCK ISLAND, Ill., Thursday, Nov. 1, 2018 – Global mobility solutions provider, AM General, today announced that it has made an investment in Mandus Group, an innovator of artillery solutions based on soft recoil technology, headquartered in Rock Island, Illinois.

November 1st, 2018|Press Center|

vTv Therapeutics Announces Transfer of Listing to The Nasdaq Capital Market

HIGH POINT, N.C.–(BUSINESS WIRE)–Oct. 29, 2018– vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease (AD) and diabetes, today announced that The NASDAQ Stock Market LLC (“Nasdaq”) has approved the Company’s application to list its Class

October 29th, 2018|Press Center|

VALASSIS CONTINUES TO EXPAND LOCAL FOOTPRINT WITH ACQUISITION OF MARKET MAGAZINE

LIVONIA, Mich., Oct. 24, 2018: Valassis, a leader in activating consumers through intelligent media delivery, announced today that Market Magazine will join Clipper, the Valassis-owned magazine focused on local businesses, continuing the trajectory of growing its presence in the hyperlocal marketing industry. Market Magazine operates

October 24th, 2018|Press Center|

vTv Therapeutics Presents Positive Data on the Effect of Azeliragon in Patients with Alzheimer’s and Diabetes at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

HIGH POINT, N.C.–(BUSINESS WIRE)–Oct. 24, 2018– vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease (AD) and diabetes, today announced that a subgroup analysis from the azeliragon Phase 3 STEADFAST trial was presented at

October 24th, 2018|Press Center|

Scantron’s New Look Reflects Its Expertise as an Assessment and Technology Solutions Company

EAGAN, Minn.–(BUSINESS WIRE)–Scantron Corporation, a leading, global provider of assessment solutions, technology solutions and scanners and forms, is changing the way people think about the testing icon by updating its brand and positioning. For more than 40 years, Scantron has continued to supply the

October 24th, 2018|Press Center|

AM General Receives Order for 740 New HMMWVS to Support the United States Army’s Modernization Efforts

SOUTH BEND, Ind., October 22, 2018 – Global vehicle solutions provider, AM General, has received an order to provide 740 new M1152A1 High Mobility Multipurpose Wheeled Vehicles (HMMWV) to the U.S. Army National Guard as a part of their modernization initiatives valued at $89

October 23rd, 2018|Press Center|

vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

HIGH POINT, N.C.–(BUSINESS WIRE)–Oct. 16, 2018– vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will deliver an oral presentation and present a poster at the 11th Clinical Trials

October 16th, 2018|Press Center|